INTRODUCTION
Prostate cancer (PC) is the second most common cancer in men and can be cured by surgery or radiotherapy in ca 70% of cases. The first line of pharmacological treatment for the remaining cases targets the androgen receptor (AR) because prostate cells depend on its activation by androgens for their growth and proliferation 1 . Activation can be prevented by combining androgen deprivation therapy, which inhibits the secretion of androgens by the testes, with the administration of antagonists that competitively bind to the binding site of androgens in the ligand-binding domain (LBD) of AR 2 .
Two to three years into this treatment PC patients inevitably develop castration-resistant prostate cancer (CRPC) as prostate cancer cells acquire the ability to activate AR at low levels of circulating androgens and in the presence of antagonists 3 . The mechanisms of aberrant activation are not well understood but appear to include the amplification of the AR gene and AR overexpression, the expression of constitutively active AR splice variants lacking the LBD, cell signaling cross-talk and mutations in both AR and transcriptional co-regulators 4 .
AR is a large multi-domain protein composed of globular ligand-and DNA-binding domains (LBD and DBD) and an N-terminal transactivation domain (NTD) that is intrinsically disordered (ID) 5, 6 (Fig. 1a) . The function of the NTD (residues 1 to 558) is to recruit the basal transcription machinery by binding to general transcription factors either directly or assisted by transcriptional co-activators 1 . These protein-protein interactions are thought to cause the folding of binding motifs in a region of the NTD called activation function 1 (AF-1) that has not yet been characterized at high resolution (Fig. 1a,b ) 6 .
Inhibiting these interactions is considered a potential therapeutic approach for both PC and CRPC 7 , but the NTD has not been considered a suitable target for drug discovery due to its apparent lack of persistent secondary and tertiary structure.
The development of drugs that interact with ID regions has however recently been met with some success 8, 9 , and has shown that targeting them with small molecules may be a viable therapeutic approach 10, 11 . A particularly important development in this area was the recent discovery of EPI-001, an experimental drug for the treatment of CRPC identified by phenotypic screening that is efficacious both in cell lines and in an animal model of this disease 12 . In vivo EPI-001 binds irreversibly to the AR NTD and weakens its interaction with general transcription factors and transcriptional co-activators 13 .
The discovery of EPI-001 represents an important milestone and a derivative of this compound is currently in clinical trials for CRPC (NCT02606123). The lack of a detailed understanding of the structural features of the domain and of the mechanism of action of this class of compounds represents, however, a hurdle for the rational design of optimized inhibitors. Here we reveal, by using solution nuclear magnetic resonance (NMR) spectroscopy, the structural properties of the ID regions of the NTD predicted to have a high propensity to fold and show that EPI-001 targets a region of sequence, known as transcription activation unit 5 (Tau-5), that is key for the ability of prostate cells to proliferate in the absence of androgens. Chemical synthesis of EPI-001 and stereoisomers EPI-001 contains two stereogenic centers and can therefore be found as two pairs of enantiomers. We synthesized the four isomers with high diastereo-and enantioselectivity (Chiral HPLC). The synthesis followed the sequence detailed in 
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As previously reported 5, 6, 15 the sequence of the NTD has features typically encountered in ID regions 16 . It has a high content of Gly, Pro, polar and charged residues and, as and transcriptional co-regulators 15 ( Fig. 1c,d ,e).
A number of studies have aimed at identifying the regions of sequence of AF-1 that are essential for transcriptional activity 18, 19 . Two large regions of sequence, known as transcription activation units 1 and 5 (Tau-1, 102-371 and Tau-5, 361-537) have emerged as especially important (Fig. 1b) . Tau-1 is crucial for the transcriptional activity of AR when the receptor is activated by androgens 18 . Although Tau-5 is less well characterised, it has been shown to be more important than Tau-1 when activation occurs via androgen independent mechanisms in androgen depletion independent cell lines derived from CRPC patients and mouse xenograft models of PC 20, 21 . Efforts have also been directed at identifying the critical stretches of residues within these regions and suggest that for Tau-1 they correspond to residues 174 to 204 (core Tau-1) 19 , and for Tau-5 to residues 433 to 437 (WHTLF motif) 20 ( Fig. 1c) .
AF-1* is partially folded
To investigate the structural properties of the NTD and its interaction with EPI-001 we cloned, expressed, purified and studied by NMR at 278K a 308-residue construct (AF-1*, residues 142-448) containing the part of AF-1 predicted to have a low disorder propensity ( Fig. 1b and 1c) , that is flanked by polyGln and polyGly tracts (Fig. 1b) . In agreement with previous reports based on the use of other biophysical methods 6 the 1 H, 15 N-HSQC spectrum of AF-1* had the features expected in an ID region such as low H N chemical shift dispersion (Fig. 2a) . In addition, and contrary to what is the case for NTD constructs containing residues 1 to 141, which include the polyQ tract (Fig. 1b) , this region of the NTD was sufficiently stable to allow a characterization of its structural properties by solution NMR.
In spite of its ID nature, the AF-1 region of the NTD has been shown to have helical propensity by circular dichroism (CD) in buffer and in the presence of cosolvents that stabilize intramolecular hydrogen bonds, as well as in the presence of the natural osmolyte trimethylamine oxide (TMAO) 5, 22 . To identify the regions of sequence that adopt this secondary structure we assigned the resonances of AF-1* by a divide and conquer approach (see Methods), compared the Cα and Cβ chemical shifts, which are reliable reporters of secondary structure, to those predicted for disordered AF-1* (Fig.   2b ) 23 and used the SSP algorithm of Forman-Kay and co-workers 24 to quantify the secondary structure propensity for the various residues of this construct from analysis of the backbone ( 13 Cα, 13 Cβ, 13 ( Fig. 2b, c) . In addition to identifying regions of helical secondary structure the analysis of the chemical shifts also suggests that residues 144-154 and 270-290 of AF-1* adopt an extended conformation (ΔδCα-ΔδCβ ≈ -0.5 ppm and SSP ≈ -0.3) (Fig. 2b, c) .
To further characterize the structural properties of AF-1* we characterized the dynamics of AF-1* by measuring the transverse relaxation rates (R 2 ) of the backbone 15 N nuclei.
Such relaxation rates are good reporters of nascent secondary structure and transient tertiary contacts in chemically denatured and ID proteins 25 . The results that we obtained, presented in figure 2d , indicate that the regions with nascent secondary structure revealed by the analysis of the 13 C chemical shifts (Fig. 2b) and presenting, in two cases, high helical propensity.
Some of the regions of sequence that we identified as partially folded in AF-1* correspond in fact to the epitopes of binding partners of AR or are known to be important for the function of this receptor. In Tau-1, for example, the region that is most structured corresponds to core Tau-1 (Fig. 2b) (Fig. 1e) .
In Tau 33, 34 and to histone acetyltransferase p300 35 ; in addition it has been shown to be indispensable for transcriptional activity in androgen depletion independent cell lines 20 .
We noted that the helical propensity of the partially folded regions identified in both Tau-1 and Tau-5 (SSP ≈ 0.5, corresponding to a population of helix of ca 50%) is substantially higher than that predicted by algorithms that solely consider local interactions such as Agadir 36 ( Figs. 1e and 2b, c) , indicating that non-local interactions may contribute to stabilizing the secondary structure. We thus investigated whether such non-local interactions included intramolecular contacts between residues in Tau-1 and Tau-5, similarly to what has been shown to occur in globular proteins under mild denaturing conditions 37 . For this analysis we used an NTD construct encompassing the part of Tau-5 contained in AF-1*, corresponding to residues 330-448 (termed Tau-5*, Fig. 1b) . We compared the H N and 15 N chemical shifts of Tau-5* to those of AF-1* and observed that they were highly similar (Fig. S2) . These results indicate that the chemical environment that residues in the Tau-5 region experience is the same both in the presence and absence of Tau-1. We conclude that the secondary structure present in AF-1* does not rely on long-range interactions between residues in Tau-1 and residues in Tau-5.
EPI-001 interacts reversibly with Tau-5
It has been proposed that the mechanism of action of EPI-001 (Fig. 3a) involves two steps 13 with AF-1* is sufficiently slow to allow the study of the reversible interaction by NMR (Fig. S5) .
The results that we obtained, shown in figures 3b and c, indicate that EPI-001 causes small but highly reproducible changes in 15 does not interact with them ( Fig. S3 ) and confirming that residues 354-448 must simultaneously be present because they are necessary for binding this compound or for stabilizing the bound state of Tau-5* (Fig. 4) .
It is interesting to note that Tau-5, the region of sequence of the NTD targeted by EPI-001, is partially folded, but it is important to emphasize that the data that we have obtained do not provide us with a mechanism of molecular recognition. It is possible that a conformational selection mechanism operates i.e. that EPI-001 interacts with a subset of the conformations that Tau-5* samples in equilibrium, but also that EPI-001 induces a new conformation in Tau-5*. Further work will be necessary to differentiate these two scenarios.
EPI-001 has two stereogenic centers and can therefore be found as four stereoisomers.
To investigate whether the interaction between this compound and Tau-5 is stereospecific we synthesized the four stereoisomers (details available as SI) and studied their interaction with AF-1* by NMR. The results that we obtained (Fig. S4) indicate that the four compounds can interact with the NTD of AR, and thus the interaction appears to occur with little or no stereoselectivity. These results are in agreement with results obtained in vivo by Myung et al, who found that, although one of the stereoisomers tested was slightly more active than the other ones, the inhibitory activity of the four stereoisomers was similar. 13 Put together our results indicate that AF-1 is partially folded in regions of sequence that correspond to those which are functionally relevant for interacting with the transcription machinery and co-regulators of transcription. In addition, they reveal that Tau-1 and Tau-5, the two independent transcription activation units that are found in AF-1, correspond to different sub-domains that appear not to be involved in long-range interactions i.e. are structurally and dynamically, at least under our conditions, independent. Finally, and most importantly, they show that Tau-5, that plays a particularly important role in AR activation in the absence of androgens, can be targeted by compounds such as EPI-001 (Fig. 4) . Although the lack of stereoselectivity that we observe suggests that the binding mode of EPI-001 may not be sufficiently well-defined for conventional drug development our results are of relevance for drug discovery for CRPC because they suggests that the NTD, and Tau 
